513 Vedolizumab, a monoclonal antibody, is used primarily for the treatment of moderate-to-severe UC by targeting 47 integrins, blocking the homing pathway of colonic lymphocytes, and reducing the inflammatory response in the intestinal tract
The full thymosin beta-4 molecule has been studied for its role in cell migration, angiogenesis, and wound repair (Goldstein et al., Expert Opinion on Biological Therapy, 2012)
These molecular interactions facilitate activation of the Ras/RAF/MEK/ERK pathway, quantifiable through phospho-specific antibody detection and real-time PCR analysis of immediate early gene expression profiles
To confirm Andexxas clinical benefit AstraZeneca used data from the Phase IV ANNEXA-I study, which found that the drug could induce significantly better hemostasis in patients with acute intracranial bleeding than usual care